GHENT, BELGIUM--(MARKET WIRE)--Sep 4, 2008 -- Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits
Ghent, BELGIUM, 4 September 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has entered into an agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to co-discover and co-develop Nanobodies® against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of EUR 10 million.
Nanobodies® are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally-occurring single domain antibodies. The partners will collaborate to research and develop Nanobody®-based therapeutics against two disease targets exploiting some of the key benefits Nanobodies® have over conventional antibodies and other fragments.
Under the terms of the agreement, both companies will equally share all research and development costs. Should Ablynx contribute equally to each program, it will be eligible to receive fifty percent of the resulting profits. In addition, Ablynx will have an option to opt-out partly or fully during the research and development programs, in which case the company would be eligible to receive either a reduced profit share, in the case of a partial opt-out, or milestones and royalties on potential sales, in the case of a full opt-out. Total development and commercial milestones, depending on the point of opt-out by Ablynx, could reach up to EUR 325 million should a product be approved in multiple indications in all major markets.
“This collaboration reinforces our commitment to deliver innovative treatments in areas of high unmet medical needs,” said Dr Bernhard Kirschbaum, Executive Vice President Research of Merck Serono. “We believe that Nanobodies® have the potential to provide innovative drugs combining the best features of monoclonal antibodies and small molecules, and we look forward to working with Ablynx.”
For more information, please contact: College Hill Life Sciences - for UK/International media enquiries: Sue Charles, Justine Lamond, John McIntyre t: +44 (0)20 7866 7857 f: +44 (0)20 7866 7900 e: ablynx@collegehill.com
Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com
Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com
Complete version of the press release in English: http://hugin.info/137912/R/1248695/270790.pdf
Copyright © Hugin AS 2008. All rights reserved.
Contact: Source: Ablynx
